Repotrectinib
- Generic Name
- Repotrectinib
- Drug Type
- Small Molecule
- Chemical Formula
- C18H18FN5O2
- CAS Number
- 1802220-02-5
- Unique Ingredient Identifier
- 08O3FQ4UNP
- Indication
用于ROS1阳性的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
- Conditions
- Advanced CancerMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 77
- Registration Number
- NCT05004116
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Instituto Oncológico Dr Rosell
- Target Recruit Count
- 32
- Registration Number
- NCT04772235
- Locations
- 🇪🇸
Hospital Regional Universitario de Málaga, Málaga, Andalucia, Spain
🇪🇸Hospital Son Espases, Palma, Baleares, Spain
🇪🇸Hospital Universitario Gregorio Marañón, Madrid, Spain
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Conditions
- Metastatic Solid TumorsLymphomaPrimary CNS TumorsLocally Advanced Solid Tumors
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT04094610
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸University of California at Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital Colorado - Anschutz Medical Campus, Aurora, Colorado, United States
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Conditions
- Locally Advanced Solid TumorsMetastatic Solid Tumors
- Interventions
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT03093116
- Locations
- 🇨🇳
Local Institution - 6504, Shatin, Hong Kong, China
🇺🇸City Of Hope, Duarte, California, United States
🇺🇸Local Institution - 2120, Glendale, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.